$0.98
6.92% today
Nasdaq, Aug 12, 04:49 pm CET
ISIN
US88688T1007
Symbol
TLRY

Tilray, Inc. Series 2 Stock price

$0.92
+0.34 58.48% 1M
-0.02 2.07% 6M
-0.41 30.83% YTD
-0.87 48.46% 1Y
-2.93 76.10% 3Y
-6.01 86.72% 5Y
-21.47 95.89% 10Y
-21.47 95.89% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.27 41.82%
ISIN
US88688T1007
Symbol
TLRY
Industry

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$1.1b
Net debt
$46.4m
Cash
$256.4m
Shares outstanding
1.1b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.2 | 1.1
EV/Sales
1.3 | 1.2
EV/FCF
negative
P/B
0.7
Financial Health
Equity Ratio
72.9%
Return on Equity
-144.7%
ROCE
-6.0%
ROIC
-6.1%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$821.3m | $894.8m
EBITDA
$-19.2m | $65.9m
EBIT
$-107.8m | $-86.6m
Net Income
$-2.2b | $-198.3m
Free Cash Flow
$-127.5m
Growth (TTM | estimate)
Revenue
4.1% | 9.0%
EBITDA
-57.0% | 443.4%
EBIT
-11.2% | 19.7%
Net Income
-792.7% | 90.9%
Free Cash Flow
-112.0%
Margin (TTM | estimate)
Gross
29.3%
EBITDA
-2.3% | 7.4%
EBIT
-13.1%
Net
-266.3% | -22.2%
Free Cash Flow
-15.5%
More
EPS
$-2.2
FCF per Share
$-0.1
Short interest
17.0%
Employees
3k
Rev per Employee
$310.0k
Show more

Is Tilray, Inc. Series 2 a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Tilray, Inc. Series 2 Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Tilray, Inc. Series 2 forecast:

7x Buy
47%
8x Hold
53%

Analyst Opinions

15 Analysts have issued a Tilray, Inc. Series 2 forecast:

Buy
47%
Hold
53%

Financial data from Tilray, Inc. Series 2

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
May '25
+/-
%
821 821
4% 4%
100%
- Direct Costs 581 581
3% 3%
71%
241 241
8% 8%
29%
- Selling and Administrative Expenses 259 259
3% 3%
32%
- Research and Development Expense 0.28 0.28
58% 58%
0%
-19 -19
57% 57%
-2%
- Depreciation and Amortization 89 89
5% 5%
11%
EBIT (Operating Income) EBIT -108 -108
11% 11%
-13%
Net Profit -2,187 -2,187
793% 793%
-266%

In millions USD.

Don't miss a Thing! We will send you all news about Tilray, Inc. Series 2 directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tilray, Inc. Series 2 Stock News

Neutral
GlobeNewsWire
about 5 hours ago
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc . (“Tilray”) (NASDAQ: TLRY and TSX: TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format extensions from its brands: Fizzy Jane's and Happy Flower.
Positive
Forbes
about 5 hours ago
Tilray Brands (NASDAQ:TLRY), a pharmaceutical company that focuses on the production and distribution of medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods, offers an intriguing value opportunity after the stock surged by 42%, driven by regulatory optimism. The administration of President Trump is contemplating the reclassification of marijuana as a less harmful drug...
Positive
Proactive Investors
about 20 hours ago
Cannabis stocks moved sharply higher on reports that President Donald Trump is considering rescheduling marijuana to a less restrictive drug category. The move would see marijuana reclassified from a Schedule I drug, along with heroin and cocaine, to Schedule III.
More Tilray, Inc. Series 2 News

Company Profile

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment sales consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment sales consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.

Head office United States
CEO Irwin Simon
Employees 2,650
Founded 2018
Website www.tilray.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today